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THE first chemotherapeutic agent used for the treatment of chronic granulo-
cytic leukaemia was the heavy metal arsenic, which as early as 1865 was noted
by Lissauer to exert a beneficial action in some cases. Radiotherapy as a treat-
ment for this condition was first used in 1902 by Pusey and was found to be
more predictable in action than arsenic. Over the next 50 years a wide variety
of drugs was tried in the management of chronic granulocytic leukaemia but none
was as satisfactory as radiotherapy which throughout this time remained the
standard therapy. In 1953 Haddow and Timmis showed that the sulphonic acid
ester busulphan (1-4 dimethanesulphonyloxybutane, Myleran, Burrows Wellcome
& Co.) caused depression of granulopoiesis in man. Galton (1953) was the first to
use this agent in the treatment of chronic granulocytic leukaemia and his results
showed that this drug was capable of challenging radiotherapy as the treatment
of choice.
Chronic granulocytic leukaemia is a relatively rare disease and although the
large majority of untreated patients survive only three to four years, occasional
patients may survive for eight to nine years (Minot, Buckman and Isaacs, 1924).
Thus the final assessment ofany new therapy requires considerable time. We have,
over the past five years, treated 25 patients with chronic granulocytic leukaemia
by busulphan and it is felt that a report of our experience may be of value. A
preliminary report concerning five of these patients has previously been published
(Nelson and Lowry, 1957). In addition, five of the patients in the present series
have shown a very high platelet count during the course of their illness and it is
of special interest that in four this occurred whilst they were on continuous
busulphan therapy.
We have used busulphan in initial dosage of 4-6 ing. daily; subsequent
control of dosage was as previously described by Nelson and Lowry (1957).
Throughout the period of initial therapy all patients were hospitalized and given
a high protein diet with a high fluid intake; blood transfusions were given only
as supportive therapy. After discharge the patients were reviewed at least once
a month as out-patients, and by the use of continuous busulphan therapy it was
attempted to keep the white cell count in the range 10-20,000/cu.mm. but
preferably below 12,000/cu.mm.
RESULTS
The results of busulphan therapy are best considered under two separate
headings:
(a) Patients in whom it was the initial therapy.
(b) Patients in whom it was given following radiation or other chemo-
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Group (a)
This group of 16 patients who all presented with the typical haematological
picture ofchronic granulocytic leukaemia, contained seven males and nine females,
varying in age from 24 to 67 years. Fourteen of these patients were treated by
us throughout and two (cases 12 and 16) were referred after therapy elsewhere.
Twelve of the 14 patients given busulphan initially by us achieved complete
clinical and haematological remissions as did the two patients treated elsewhere.
Thus, we have had the opportunity of observing 14 patients who made satis-
factory responses to initial busulphan therapy (Table I) Details of these patients
TABLE I.-Initial Response to Busulphan
Number Response
of ,
Previous therapy cases Good Poor
Nil . . . 16 .14 2
Radiotherapy-Resistant . 4 .- 4
-Non-resistant . 2 . 2
6-mereaptopurine . . . 2 1 1
Triethylene melamine . 1 . 1
Total . 25 . 18 7
TABLE I.-Response to Initial Therapy with Busulphan
Case
No. Age
1 . 26
2 . 61
Initial
Initial response
W.C.C./ to
Sex cu. mm. busulphan
. M. . 112,000 . Good
. M. . 293,000 . Good
3 . 59 . F. 338,000
4 63 . F. . 309,000
5 .67 M.. 88,000.
6 . 53 M. . 164,000
7 . 49 . F. . 270,000 .
8 . 67 . F. . 264,000 .
9 . 66 . F. . 138,000
10 .50 F. .295,000.
11 . 53 . F. . 28,000
12 . 42 . M. . 88,000
65
34
57
24
M.
M.
F.
F.
. 215,000
. 98,000
. 50,000
. 409,000
Subsequent course
W.C.C./ Dose in
Cu. mm.
8-26,000
3-72,000
Good 10-31,000
Poor
Poor
Good
Good
Good
Good
Good
Good
Good
Good
Good
Good
Good
6-30,000
8-24,000
. 12-24,000
5-34,000
9-18,000
9-29,000
7-14,000
8-30,000
11-26,000
4-14,000
. 10-16,000
. 10-302,000
Survival
from
diagnosis
(in
mg. daily months) Comment
0-5-1-5 49 . Terminal blastic crisis.
Nil-6 . 59 . Episode ofmarrow fail-
ure. Terminal blastic
crisis.
0-5-1-5 14 Skin pigmentation.
Terminalblastic crisis.
- i . Initial thrombocyto-
psenia. Haemorrhage.
- 3 . Initial thrombocyto-
paenia. Haemorrhage.
0-5-1-0 . 22 Myocardial infaret.
0-5-2-0 . 21 Carcinoma breast.
0-5-1-5 31+ Well controlled.
0-25-1-5 . 14+ . Well controlled.
0-5-2-0 . 26+ Well controlled.
19+ . Continued remission.
Nil-I - 5 31+ . Subsequently well con-
trolled.
0-25-1-0 . 10+ . Thrombocytosis.
0-25-1-0 7+ Well controlled.
0 5-2-0 6+ Thrombocytosis.
Nil-6 . 24+ . Subsequent resistance
to busulphan and ra-
diotherapy.
are summarized in Table II. A clinical response to therapy was usually evident
within two weeks and preceded haematological improvement in all cases. This
was first manifested by a fall in the total white cell count, the disappearance of
primitive granulocytes, and later followed by a rise in haemoglobin concentration.
13
14
15
16
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The time required to achieve remission, i.e. to reduce the white cell count to
under 20,000 per cu.min., varied from 24 to 100 days and the total dosage of
busulphan given in this initial period varied from 102 to 380 mg.
The only two patients in whom we were unable to produce a remission, both
presented with purpura associated with severe thrombocytopaenia. In one of
these (case 4) therapy did not affect the white cell count, nor was the platelet count
affected. In the other (case 5) therapy succeeded in lowering the white cell count,
but as in the previous patient, the platelet count remained unaltered. These
patients survived the initiation oftherapy by two weeks and three months respec-
tively and both died from uncontrollable gastro-intestinal haemorrhage.
Of the 14 patients making satisfactory responses nine are still alive and five
dead. Six of these nine survivors were given continuous therapy and are still in
remission, having been controlled for periods varying from six months to 31
months. The maintenance dose of busulphan varied from 0 5 mg. on alternate
days to 2-0 mg. daily. These six patients are in good health and have been able
to resume normal activities.
In the remaining three patients who still survive, busulphan was discontinued
after the initial response. One ofthese (case 12) was initially given a 14-day course
of busulphan. He first came under our observation five months later, at which
time he was still in remission with a white cell count of 8,700 per cu.mm. Five
months later, when the white cell count had risen to 30,000 per cu.mm. busulphan
was recommenced. His response was satisfetory and over the past 20 months he
has been on maintenance therapy and has remained in clinical and haematological
remission. The second patient (case 16) initially treated elsewhere with good
response, failed to re-attend for review for nine months. When first seen by us
she was in clinical and haematological relapse with a haemoglobin of 9-2 g./100 ml.
and a white cell count of 247,000 per cu.mm. Busulphan therapy was re-instituted
and although the white cell count fell to 16,000 per cu.mm. there was no improve-
ment in haemoglobin concentration or diminution of splenomegaly. Splenic irra-
diation was given, which produced a remission lasting only three months. Further
busulphan and splenic irradiation have proved unsatisfactory in controlling the
disease although the patient still remains in moderate health. The third patient
(case 11) had busulphan for one month and achieved a complete remission which
has lasted for 18 months, the white cell count remaining between 7-14,000 per
cu.mm., without anv further therapv.
Five patients are dead: two (cases 6 and 7) died from causes unrelated to
their leukaemia, namely myocardial infarct a-nd carcinoma of breast, while the
remaining three died from their chronic granulocytic leukaemia.
The two former patients (cases 6 and 7) had been in satisfactory remission on
continuous drug therapy for 22 and 21 months before death A short summary
ofthe history ofeach ofthe three patients who died from their leukaemia follows:
Case 1, a male aged 26 years, survived the institution oftherapy for 49 months.
Until two months before his death ho was able to remain at work and lead a sub-
stantially normal life with a controlled wvhite cell count. Terminally his leukaemic
process became frankly " blastic " and he died from cerebral haemorrhage. It is
of interest to note that after he had been on continuous therapy for 36 months
he became the father of a normal child.
Case 2, a male aged 61 years, after initial remission was controlled on a main-
tenance dose of 0 5 mg. daily for 12 months, before the white cell count began to
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rise again. Fluctuations in the white cell count then necessitated frequent changes
in busulphan do-sage over the next six months, the dose reaching 6 mg. daily for
a short period of time before a steady therapeutic level was again reached. How-
ever, the white cell count then continued to fall and despite withdrawal of the
drug a peripheral pancytopawnia developed. Five months after cessation of
therapy the haemoglobin level was 7-4 g./100 ml., leucocytes 3,500/cu.mm. and
platelets 50,000/cu.mm. This episode of partial marrow failure lasted eight months
during which time the haemoglobin was maintained by blood transfusions. Re-
covery then ensued and was followed by a remission lasting 12 months, the haemo-
globin concentration, white cell count and platelets during this period being
within normal limits. The leukaemic process then again became evident, and
although haematological control by busulphan was unsatisfactory and frequent
changes of dosage were needed, the patient remained in fairly good health.
Terminally a blastic phase developed and death from haemorrhage ensued 59
months after diagnosis.
Case 3, a female aged 59 years, was well controlled for 10 months on doses
varying from 0-5 to 1*5 mg. daily. From then until her death, four months later,
control was unsatisfactory, the white cell count rose as did the number of blast
cells in the peripheral blood, and she needed frequent transfusions. Coincidental
with the worsening of her condition she was noted to be developing generalised
brownish skin pigmentation which persisted, despite treatment with nicotinamide,
until her death. Autopsy revealed leukaemic deposits in the adrenal glands but
as she also had hypertension throughout the last few months of her life, it was felt
unlikely that she suffered from secondary Addison's disease. Generalised pig-
mentation has been described by other authors as a side effect of busulphan
therapy, but this is the only instance we encountered.
In these three patients the leukaemic process terminated in the same manner,
i.e. the developnment of an acute leukaemic phase. Once this phase appeared,
further therapy either with busulphan, 6-mercaptopurine or steroids had no effect.
Group (b)
Nine patients have been observed who, before commencing busulphan, were
treated by radiotherapy (6 cases), 6-mercaptopurine (2 cases) and triethylene
melamine (1 case) (Table III).
Of the six patients given initial radiotherapy, two, after making a satisfactory
response, were changed electively to busulphan for maintenance therapy, whilst
four were given busulphan when they had become radio-resistant. Case 19, a male
aged 35 years, had two courses of splenic irradiation, each of which produced a,
good remission lasting 12 months. Twelve months after the second course he
was again in relapse and treatmentwith busulphaninstandarddosage was started,
achieving a complete remission in two months. For the next 22 months he has
been satisfactorily controlled on doses ofbusulphan ranging from 0 5 mg. to IP0 ing.
daily. Case 21, a femnale aged 24 years, made a satisfactory response to an initial
course of splenic irradiation. Fifteen months later, when she was in relapse her
therapy was changed to busulphan which induced a remission in four weeks. This
continued for five months when she developed lobar pneumonia and died.
Four patients (cases 22, 23, 24 and 25), who had become resistant to radio-
therapy, were subsequently given busulphan in standard dosage and in none of
these patients was satisfactory control achieved; in all the white cell count was
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TABLE III.-Response to Busulphan after Previous Therapy
Survival Survival
W.C.C./ after from
cu.mm. Response busulphani diagnosis
C(se Previous prior to to (in (in
No. Age Sex therapy busulphan busulphan inonths) months) Cornmnent
17 18 . M. 6-miieicaptopurine 319,000 Good 6+ 9+ Alive and well.
18 18 F. 6-mercaptopurine 84,000 Poor 18+ 21 +- . Thromnbocytosis
of 3,000,000/
Cu. mm.
19 35 A. Radiotherapy 171,000 Good . 24+ 60+ Alive and well.
20 40 F. Triethylene mel- . 93,000 Good 10 23 Died. Blastic
amine termination.
21 24 . F. Radiotherapy 63,000 Goocl 6 21 Died. Lobar
pneumonia.
22 . 36 F. Radiotherapy 38,000 Poor 2 108 Died. Blastic
termination.
23 . 41 F. Radiotherapy . 63,000 Poor 11 78 Died. Cachexia.
24 59 F. Radiotherapy 91,000 Poor . 7 43 Died. Blastic
termination.
25 59 F. . Radiotherapy 87,000 Poor . 6 65 Died. Cachexia.
reduced but this was not associated with a rise in haemoglobin level or clinical
improvement. These patients all died from their leukaemia and none survived
the onset of chemotherapy by more than 11 months. In two patients, death was
preceded by a blastic crisis and two died in a cachetic state.
Two patients (cases 17 and 18) given 6-mercaptopurine initially obtained only
partial remissions and three months after diagnosis were started on busulphan.
One (case 17) made a satisfactory response to this, and his subsequent clinical
course has been uneventful for six months, during which time his white cell count
has varied between 10,000 and 25,000 per cu.mm. The other patient, a female
aged 18 years (case 18) did not make a satisfactory response to busulphan. On this
drug her white cell count tended to fluctuate and her gross splenomegaly was not
influenced. She was treated with splenic irradiation to which she made only a
temporary response. She is still alive and in fair health 21 months after diagnosis,
although in the past 12 months her condition has only been partially controlled by
the use of both chemotherapy and radiotherapy.
The patient (case 20) initially given triethylene melamine was a female aged
40 years. She had made a moderate response to this treatment, but 13 months
after diagnosis was in clinical and haematological relapse. A course of busulphan
produced a satisfactory remission which was maintained for two months. She
then failed to re-attend the clinic and when next seen six months later, she was
in a moribund state. Her peripheral blood examination showed that the leukaemic
process had undergone blastic transformation and death ensued rapidly.
The most striking feature about this group concerns those patients who had
received previous radiotherapy; those who were radio-resistant had a uniformly
poor response to busulphan, whereas those who were changed before resistance
developed had good and nmaintained remissions.
Effect of Bus8ulphan on the Platelet C(ount
Platelet counts were performed on all patients at the time of diagnosis and
also on each subsequent review. All platelet counts given are those obtained from
venous samples using the direct counting method; the normal range in this
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laboratory is taken as 200-500,000 per cu.mm. An initial platelet count in all but
three of our 25 patients lay within the range of 150,000 to 500,000 per cu.mm.;
two of these presented with thrombocytopaenia and died shortly after diagnosis,
whilst the third had an initial platelet count of 794,000 per cu.mm. In only six
patients were significant variations in the platelet count recorded throughout the
course of their illness, not associated with the development of a terminal blastic
phase. One patient (case 2) developed thrombocytopaenia associated with partial
marrow failure and five patients developed thrombocytosis. This term as used
here is defined as a platelet count of over a million on at least two consecutive
occasions.
Case 13, a male aged 65 years, had initial white cell count of 215,000 per cu.mm.
and a platelet count of 794,000 per cu.mm. After five to seven weeks treatment
before remission was established, when the white cell counts lay between 47,000
and 51,000 per cu.mm., the platelet count lay between 1-36 x 106 and 1-68 x 106
per cu.mm. The daily dose of busulphan was reduced at this time and since then
the platelet count has fallen. Over the period three to six months after the start
of the therapy, when the white cell count has been at the desired level, the platelet
count has varied from 316,000 to 646,000 per cu.mm.
Case 15, a female aged 57 years, had a white cell count of 50,500 per cu.mm.
and a platelet count of 248,000 per cu.mm. when first seen some six months ago.
After four weeks chemotherapy, the white cell count was 14,000 per cu.mm. and
the platelet count 714,000 per cu.mm. She has been kept on busulphan contin-
uously and the white cell count has been maintained between 10,000 and 16,000
per cu.mm. After 12 and 14 weeks therapy the platelet counts have been1 x 106
and 1 2 x 106 per cu.mm. respectively.
Case 17, a male aged 18 years, had a white cell count of 319,000 per cu.mm. and
the platelet count was 248,000 per cu.mm. He was initially given 6-mercaptopurine
which produced only a partial response and when changed to busulphan some
three months later his white cell count was 100,300 per cu.mm. and platelet count
was 346,000 per cu.mm. After five to six months continuous therapy, during
which time the white cell count was maintained at satisfactory levels, the platelet
count has risen to between 1-23 x 106 and 1-34 x 106 per cu.mm. respectively.
Case 18, a female aged 18 years, was initially treated with 6-mercaptopurine
with partial success. She was then given busulphan and after three to four months
continuous therapy, the platelet count had risen from 438,000 to between 1-39
x 106 and 1-75 x106 per cu.mm. respectively. Coincidentally the white cell
count was reduced, but the gross splenomegaly was not influenced and she was
given splenic irradiation. This reduced the platelet count only very temporarily.
Since that time she has been given busulphan, radio-active phosphorus, X-ray
therapy and triethylene melamine, but none of these agents has succeeded in
substantially lowering the platelet count. During the 13 months previous to
review platelet counts varying from 1-35
x 106 to 3
x 106 per cu.mm. have been
recorded.
Case 16, a female aged 24 years, diagnosed elsewhere, had a satisfactory response
to busulphan and initially the platelet count varied between 250,000 and 400,000
per cu.mm. When first seen by us she was in clinical and haematological relapse
with a white cell count of 247,000 per cu.mm. and a platelet count of 1-26 x 106
per cu.mm. She was given busulphan which reduced the white cell count but did
not affect the high platelet count or the gross splenomegaly. Radiotherapy was
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given which produced a short but good response in both the leucocyte and platelet
counts. When the white cell count started to rise, the platelet count did so also
and since that time (some nine months ago) busulphan and radiotherapy have not
significantly altered the platelet count which remains over1 x 106 per cu.mm.
DISCUSSION
All the currently available regimes of therapy for chronic granulocytic leu-
kaemia are purely palliative. The points on which the different regimes may be
judged are the initial remission rate, efficacy of control, incidence of side effects
and effect on survival. We will now discuss our results under these headings.
In the present series of 25 patients given busulphan for chronic granulocytic
leukaemia, 18 made satisfactory responses, and this incidence of initial remissions
is similar to that reported by other authors (Galton, 1953; Louis, Limarzi and
Best, 1956; Blackburn, King and Swan-, 1956; Greig, 1956; Turesson, 1957).
Seven patients failed to make a satisfactory initial response to busulphan and
of these, four had had previous radiotherapy and were resistant to it, two had
thrombocytopacnia at the time of diagnosis and one had been previously treated
with 6-mercaptopurine to which she only partially responded. Our failure to
achieve any significant remissions in the four patients who were resistant to radio-
therapy was disappointing as this had not been the experience of others (Galton,
1953; Blackburn et al., 1956; Louis et al., 1956; Hyman and Gellhorn, 1956).
It is of interest to note that two patients responding poorly to busulphan were
subsequently given splenic irradiation but made only a partial and very temporary
response to this therapy. In neither of the two patients with initial thrombocyto-
ptenia was this aggravated by busulphan therapy, although both died from haemor-
rhage. Greig (1956) treated two similar cases with busulphan and found the throm-
bocytopaenia to be accentuated. However, Hayhoe (1960) and Haut, Abbott,
Wintrobe and Cartwright (1961) have by the use of busulphan induced remissions
in patients presenting with thrombocytopaenia. Thus, it would appear that
although the response of such patients to busulphan is variable, as radiotherapy
is definitely contra-indicated, a course of this drug is worthy of trial.
Patients in whom disease is controlled by busulphan show very little clinical
or haematological evidence of their leukaemic process. They are able to resume
full activities, their haemoglobin level and leucocyte counts are in the normal
range and the only abnorniality in the differential white cell count is a slight shift
to the left in the granulocytic series and perhaps a slight increase in the number
of basophils present; splenomegaly may disappear or be greatly diminished.
Busulphan may be given either continuously or intermittently. Continuous
therapy is given in an attempt to maintain the white cell count between 10 and
20,000 per cu.mm. and thus achieve a relatively stable haematological and clinical
course. The theory in favour of intermittent therapy in which the drug is with-
drawn when the white cell count falls to under 10,000 per cu.mm. to be reintro-
duced when relapse occurs is that this regime may delay the emergence of drug
resistance.
Our experience of intermittent therapy is very limited as in only four cases
has the drug been withdrawn for periods of greater than four weeks. In one case
the withdrawal of therapy was necessitated by the development of peripheral
pancytopaenia; in this case once the erythroid and megakaryocytic elements
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recovered there was a remission of the leukaemic process for a further 12 months.
Such prolonged remissions following toxic marrow damage have been reported by
other authors. In two patients the drug was withheld because the white cell
count had fallen to under 10,000 per cu.mm.; one of these patients is still in
complete haematological remission 18 months later and in the other patient the
remission lasted for 11 months. In this latter case the drug was recommenced at
the earliest sign ofhaematological relapse and subsequent control on maintenance
therapy has been satisfactory. In the remaining patient in whom, because of her
failure to re-attend, busulphan was not given until frank clinical relapse was
established, the subsequent response was unsatisfactory. We have, however,
been impressed by the ability of maintenance therapy to keep these patients in
very good clinical and haematological control and as Galton, Till and Wiltshaw
(1958) and Bethell (1958) have shown that continous therapy is not associated
with the earlier emergence of drug resistance we would feel that this method of
therapy is the one of choice.
Compared to the earlier chemotherapeutic agents the side effects of busulphan
are surprisingly few. Gastro-intestinal intolerance occurs very rarely and although
reported recently by Ghose and Chatterjea (1960) in six out of 46 patients treated
by them we have not encountered it in any case.
The most important side effect is depression of the marrow elements. The
incidence of this complication depends largely on the dose of the drug used. It
was seen more frequently in the earlier days of busulphan therapy when daily
doses of the order of 16 mg. were given. It is now, however, generally agreed
that the only advantage of these larger doses is to induce a more rapid response
and that equal benefit can be derived from the less intensive therapy as used in
the present series. Hayhoe and Kok (1957) have reported a patient who unexpect-
edly developed marrow failure while on a moderate dosage and a similar case
previously reported by one of us (Nelson and Lowry, 1957) is included in the
present series. The possibility of marrow failure occurring in patients on moderate
doses of the drug makes it important that all patients on busulphan should be
reviewed at least once a month and at each visit their haemoglobin level, leucocyte
and platelet counts should be determined.
One case of generalised skin pigmentation was encountered after busulphan
had been given for ten months. This complication had been previously noted
(Dameshek and Gunz, 1958; Hayhoe, 1960) but the aetiology of this condition
is not clear. Cutaneous pigmentation may occur in patients with a wide variety
of malignant diseases and it may well be that this is a complication more of the
underlying leukaemic process rather than of the therapy.
The effect of busulphan on the sex glands of the experimental animal and the
human is not yet clearly established. In the experimental animal, e.g. the rat,
the drug causes infertility by interfering with spermatogenesis (Jackson, Fox and
Craig, 1959) an-d sterility and azoospermia in the human have been recorded by
Wilkinson and Turner (1959). It is of interest that one of our patients, aged 26
years, became the father of a normal child after continuous busulphan therapy
for three years. Amenorrhoea has been described as a side effect of busulphan
therapy by Ghose and Chatterjea (1960) who noted it in six of 13 patients and by
Louis et al. (1956) who noted it in all four of their female patients in the relevant
age group. Six of our female patients were in the reproductive span of life. In
two of them amenorrhoea was present before diagnosis persisted, whilst in the
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other four no disturbance in menstruation was noted. These findings would tend
to suggest that at the level ofdosage employed in the present series little effect on
the sex glands, either in the male or female, occurs.
The present series gives very little information as to the effect of busulphan
on survival time of patients with chronic granulocytic leukaemia. We have only
three patients who made an initial response to busulphan, were maintained on the
drug and subsequently died from their leukaemia; these patients survived
diagnosis by 14, 49 and 59 months. Amongst our patients who died from leu-
kaemia but at some stage received therapy other than busulphan the longest
survival was 108 months. Of our patients who still survive the longest interval
which has elapsed since diagnosis is 60 months. Thus the survival time of none of
our patients is remarkable as Minot et al. (1924) found that occasional untreated
patients survived for up to nine years. Galton etal. (1958) and GhoseandChatterjea
(1960) have found that busulphan, like radiotherapy, does not significantly prolong
life and our limited experience of the drug would lead us to agree with them.
Wilkinson and Turner (1959) suggest that the somewhat paradoxical situation
whereby busulphan which is undoubtedly effective in producing complete remis-
sions but does not appear to significantly prolong life, may be due to the fact
that patients so treated have a greater frequency of blastic crises. Blackburn
et al. (1956) were the first to suggest that the use of busulphan might be attended
by a greater frequency of this complication. In our present series eight patients
who initially responded to some form of therapy, subsequently died from their
leukaemia. In six of these patients the terminal event was blastic transformation
of the leukaemic process and the remaining two died from anaemia and cachexia.
Blastic crises were reported by Shimkin, Mettier and Bierman (1951) in 16 out of
64 untreated cases studied at autopsy, an incidence of 25 per cent, and Louis,
Best and Limarzi (1957) found an incidence of 59 per cent in a series of 27 cases.
Although Wilkinson and Turner (1959) came to the conclusion from their review
that the incidence was increased, Haut et al. (1961) found, from a review of the
literature and their own series, that approximately 50 per cent of patients with
chronic granulocytic leukaemia, whether untreated or given busulphan, developed
a blastic termination. That busulphan increases the frequency of blastic termina-
tion cannot be regarded as proven and it seems likely that this point will be most
difficult to confirm owing to the lack of information on the manner of termination
of untreated patients with chronic granulocytic leukaemia.
It is well recognised that in chronic granulocytic leukaemia the platelet count
is very variable and in our series of 25 patients the platelet counts lay between
40 and 794,000 per cu.mm. at the time of diagnosis. The effect of busulphan on
the platelet count in chronc granulocytic leukaemia is unpredictable but in the
majority of patients it remains within normal limits. Many authors have empha-
sized the possibility of this drug having a toxic effect on the megakaryocytes
(Hyman and Gellhorn, 1956; Louis et al., 1956; Turesson, 1957) and indeed
we have seen one such case. However, the more striking effect which we en-
countered in the present series has been thrombocytosis which occurred in five
of our 25 patients. In one patient the thrombocytosis was first noted at the time
offrankhaematologicalrelapseafteraninitial satisfactoryremissionwithbusulphan.
In the other four patients the high platelet counts developed whilst on continuous
busulphan therapy and were noted at a time when the leucocyte counts were either
partially or completely controlled. In no case was the thrombocytosis associated
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with any clinical manifestations. It is difficult to understand why in some cases
busulphan may cause a toxic thrombocytopa-nia whilst in others, in which as
judged by the white cell count the drug appears to be effective, thrombocytosis
develops.
In our experience, busulphan induced remission in a high percentage ofpatients
with chronic granulocytic leukaemia and in the majority ofthese patients this was
maintained by the use of continuous therapy. These benefits were obtained with
few serious side effects, although unexpected marrow failure occurred in one
patient. The incidence of remissions obtained by the use of busulphan is equal to
that following radiotherapy (Ghose and Chatterjea, 1960) and it is generally
agreed that neither regime significantly prolongs survival. However, as drug
therapy is easier to administer and less unpleasant for the patient, we consider
that busulphan is the initial treatment ofchoice for chronic granulocytic leukaemia.
The fact that neither regime prolongs survival would suggest that neither radio-
therapy nor chemotherapy alters the basic defect, whatever that may be, in
chronic granulocytic leukaemia and curative therapy for this condition must await
further advances.
SUMMARY
The results of treatment of 25 cases of chronic granulocytic leukaemia by
busulphan are recorded. Of 16 patients given this drug as initial therapy, 14 made
satisfactory responses; the two who failed to respond had severe thrombocyto-
paenia at the time of diagnosis. Six patients had previous radiotherapy; two
were changed electively to busulphan for maintenance therapy and achieved
good responses, whilst four who had become resistant to radiotherapy showed no
worthwhile improvement. Maintenance therapy with busulphan proved very
satisfactory, stable haematological and clinical courses being achieved in the large
majority of cases.
Toxic effects were few, the only serious one being temporary marrow depres-
sion, which occurred unexpectedly in one patient. No increase in longevity was
noted and there was a high incidence of terminal blastic crises. Five patients
developed thrombocytosis and in four this occurred whilst on maintenance therapy
with busulphan.
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